Items Tagged ‘HER-2’

March 26, 2018

FDA Approves Perjecta for Adjuvant Treatment of HER2-positive Breast Cancer

By

CancerConnect News: On December 20, 2017, the Food and Drug Administration granted regular approval to Perjeta (pertuzumab) for use in combination with Herceptin (trastuzumab) and chemotherapy as adjuvant treatment of patients with HER2-positive early stage breast cancer at high risk of recurrence. About Perjeta Breast cancer is the second leading cause of cancer-related death among […]

View full entry

Tags: Breast Cancer, HER-2, neu positive, News, perjeta, pertuzumab


November 1, 2017

Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer

By

Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy (ExteNET trial) were presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. About HER2-Positive Breast Cancer Approximately 20% to 25% of breast cancers over-express the HER2 protein. HER2-positive […]

View full entry

Tags: Breast Cancer, HER-2, HER4 Positive Early Stage Breast Cancer, herceptin, Nerlynx HER1, News, Precision Cancer Medicine, trastuzumab